TH-302 is designed to release cytotoxic bromo-isophosphoramide (Br-IPM) moiety in hypoxic microenvironment. Therefore, this drug preferentially attacks the hypoxic region in cancer where other standard anti-cancer treatment such as chemotherapy and radiation therapy are ineffective. Here, we monitored the change in tumor hypoxia and perfusion in response to TH-302 treatment by EPR oximetry and DCE MRI using two pancreatic ductal adenocarcinoma xenograft models. The result showed improved oxygenation only in treatment sensitive MIA Paca-2 tumors without modulating tumor blood perfusion, suggesting that intratumor pO2 is a useful biomarker to evaluate treatment response to TH-302.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords